Metabolic Deals Speed a New US Race to Transform Liver Care

Novo Nordisk’s move for Akero boosts momentum in metabolic care; industry players should prepare for faster shifts in liver-disease treatment

9 Dec 2025

Novo Nordisk’s plan to buy Akero Therapeutics, valuing it at about $60 a share through upfront and milestone payments, has stirred fresh urgency in metabolic medicine. The move comes as firms rush to secure an edge in treating liver disease linked to obesity, a field long marked by high hopes and thin results.

Akero’s appeal lies in efruxifermin, a late-stage drug that early studies suggest can cut liver fat and inflammation, the dual forces behind steatohepatitis, now labelled MASH. Millions of Americans have the condition, yet doctors have few options to slow its advance. That scarcity means even modest clinical progress attracts investors and researchers who view MASH as one of the decade’s largest care gaps.

For Novo Nordisk, already dominant in diabetes and weight management, the purchase extends its reach across the metabolic map. Analysts see the bet as part of a wider shift, since drugmakers are starting to link obesity drugs with therapies that shield the liver. One strategist argued that whoever brings these strands together first could set a template for integrated metabolic care.

The market is moving quickly. Rising obesity is driving demand for treatments that ease symptoms and prevent long-term damage. Bold steps such as Novo’s show confidence in a field poised for expansion, even as the science remains uncertain and regulators prepare their usual hurdles. Competitors are speeding up their own trials, raising the stakes for would-be leaders.

Even so, sentiment in the sector is bright. A senior researcher at another metabolic group called liver disease “one of the largest opportunities in the field” and said early movers will shape future standards. Many expect this moment to spark new partnerships and long-awaited therapies for an underserved population.

More assertive dealmaking seems assured. For now, Novo Nordisk’s bid signals that the race to redefine liver care is already under way.